Donanemab physiologically based pharmacokinetic model coupled with natural life cycle model for amyloid plaque aggregation to predict target CSF and ISF concentrations associated with amyloid plaque reduction

Abstract

Background: Whole body physiologically based pharmacokinetic (PBPK) models describe the disposition of antibody therapeutics into the CNS and are used to simulate dynamics of cerebrospinal (CSF) and interstitial (ISF) fluid.